- Minafin Group appoints Olivier Ubrich as CEO of its Health Chemistry division, overseeing Minakem CDMO and Generics.
- Ubrich’s leadership will focus on international growth, leveraging synergies, and driving technological innovation.
The Minafin Group has appointed Olivier Ubrich as CEO of its Health Chemistry division, which encompasses Minakem CDMO and Minakem Generics & New Therapies.
Ubrich, who joins the Minafin Executive Committee, brings extensive international experience. He previously held leadership roles at BASF and Mettler Toledo AutoChem in the United States. He holds a Process Engineering degree and completed his doctoral thesis in partnership with Novartis and the École Polytechnique Fédérale de Lausanne.
“Olivier’s expertise as a world-class leader and his deep understanding of the high-value life sciences market are invaluable assets for Minafin,” said Frédéric Gauchet, Chairman of the Minafin Group. “We are confident that he will accelerate our growth in pharmaceutical active ingredients, particularly small molecules and those associated with new therapies. Under his leadership, we will continue to provide our customers with the services they need to deliver efficient and reliable treatments to patients.”
“I am honored to join Minakem, a team renowned for its expertise in chemical synthesis and agility in the field of pharmaceutical active ingredients,” said Olivier Ubrich. “Building on Minakem’s rich history of innovation and strong partnerships, I am committed to expanding our global impact on healthcare. Together, we have the potential to create a better future for our customers and improve lives through our contributions.”
Overview of outsourcing trends 
